Mainstream Media Blackout on nasal spray that is 99% effective against Covid-19 in its Phase 3 clinical trial.
The Canadian pharmaceutical company SaNOtize Research & Development Corp., (SaNOtize), and Glenmark Pharmaceuticals Limted (Glenmark), announced earlier this month the successful outcomes of a nasal spray in its Phase 3 clinical trials and now approved by India's drug regulator as a treatment for adult patients with Covid-19 who have a risk of progression of the disease.
The SaNOTize Nitric Oxide Nasal Spray (NONS) reduced the SARS-CoV-2 log viral load in Covid-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours as compared to saline control.
NONS has a marketing authorization as Class 1 Medical Device in the EU, and is also approved and being sold in Israel, Thailand, Indonesia and Bahrain, under the name enovid or VirX.
Comments
Post a Comment